These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 33811251

  • 1. Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines.
    Wang W, Liu P, Lavrijsen M, Li S, Zhang R, Li S, van de Geer WS, van de Werken HJG, Peppelenbosch MP, Smits R.
    Sci Rep; 2021 Apr 02; 11(1):7470. PubMed ID: 33811251
    [Abstract] [Full Text] [Related]

  • 2. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L, Wang X, Jia T, Wei W, Chua MS, So S.
    Oncotarget; 2015 Sep 22; 6(28):25390-401. PubMed ID: 26246473
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.
    Bao R, Christova T, Song S, Angers S, Yan X, Attisano L.
    PLoS One; 2012 Sep 22; 7(11):e48670. PubMed ID: 23144924
    [Abstract] [Full Text] [Related]

  • 4. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S, Dahmani R, Coulouarn C, Ragazzon B, Mlecnik B, Senni N, Savall M, Bossard P, Sohier P, Drouet V, Tournier E, Dumont F, Sanson R, Calderaro J, Zucman-Rossi J, Vasseur-Cognet M, Just PA, Terris B, Perret C, Gilgenkrantz H.
    J Hepatol; 2018 Jun 22; 68(6):1203-1213. PubMed ID: 29525529
    [Abstract] [Full Text] [Related]

  • 5. Unraveling the impact of AXIN1 mutations on HCC development: Insights from CRISPR/Cas9 repaired AXIN1-mutant liver cancer cell lines.
    Zhang R, Li S, Schippers K, Eimers B, Niu J, Hornung BVH, van den Hout MCGN, van Ijcken WFJ, Peppelenbosch MP, Smits R.
    PLoS One; 2024 Jun 22; 19(6):e0304607. PubMed ID: 38848383
    [Abstract] [Full Text] [Related]

  • 6. Differential Roles of AXIN1 and AXIN2 in Tankyrase Inhibitor-Induced Formation of Degradasomes and β-Catenin Degradation.
    Thorvaldsen TE, Pedersen NM, Wenzel EM, Stenmark H.
    PLoS One; 2017 Jun 22; 12(1):e0170508. PubMed ID: 28107521
    [Abstract] [Full Text] [Related]

  • 7. Formation of Tankyrase Inhibitor-Induced Degradasomes Requires Proteasome Activity.
    Pedersen NM, Thorvaldsen TE, Schultz SW, Wenzel EM, Stenmark H.
    PLoS One; 2016 Jun 22; 11(8):e0160507. PubMed ID: 27482906
    [Abstract] [Full Text] [Related]

  • 8. Coordinated action of Axin1 and Axin2 suppresses β-catenin to regulate muscle stem cell function.
    Figeac N, Zammit PS.
    Cell Signal; 2015 Aug 22; 27(8):1652-65. PubMed ID: 25866367
    [Abstract] [Full Text] [Related]

  • 9. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, Machon O, Korinek V, Choo E, Diaz D, Merchant M, Polakis P, Holsworth DD, Krauss S, Costa M.
    Cancer Res; 2013 May 15; 73(10):3132-44. PubMed ID: 23539443
    [Abstract] [Full Text] [Related]

  • 10. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W.
    Oncogene; 2002 Jul 18; 21(31):4863-71. PubMed ID: 12101426
    [Abstract] [Full Text] [Related]

  • 11. Alterations of axis inhibition protein 1 (AXIN1) in hepatitis B virus-related hepatocellular carcinoma and overexpression of AXIN1 induces apoptosis in hepatocellular cancer cells.
    Li J, Quan H, Liu Q, Si Z, He Z, Qi H.
    Oncol Res; 2013 Jul 18; 20(7):281-8. PubMed ID: 23879168
    [Abstract] [Full Text] [Related]

  • 12. CCAAT/enhancer-binding protein-β functions as a negative regulator of Wnt/β-catenin signaling through activation of AXIN1 gene expression.
    Park S, Lee MS, Gwak J, Choi TI, Lee Y, Ju BG, Kim CH, Oh S.
    Cell Death Dis; 2018 Oct 03; 9(10):1023. PubMed ID: 30283086
    [Abstract] [Full Text] [Related]

  • 13. Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling.
    Wang W, Li S, Liu P, Sideras K, van de Werken HJG, van der Heide M, Cao W, Lavrijsen M, Peppelenbosch MP, Bruno M, Pan Q, Smits R.
    Mol Cancer Res; 2019 Feb 03; 17(2):521-531. PubMed ID: 30257989
    [Abstract] [Full Text] [Related]

  • 14. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
    Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y.
    Nat Genet; 2000 Mar 03; 24(3):245-50. PubMed ID: 10700176
    [Abstract] [Full Text] [Related]

  • 15. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
    Martino-Echarri E, Brocardo MG, Mills KM, Henderson BR.
    PLoS One; 2016 Mar 03; 11(3):e0150484. PubMed ID: 26930278
    [Abstract] [Full Text] [Related]

  • 16. The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt.
    Regmi SC, Park SY, Kim SJ, Banskota S, Shah S, Kim DH, Kim JA.
    PLoS One; 2015 Mar 03; 10(11):e0141753. PubMed ID: 26544726
    [Abstract] [Full Text] [Related]

  • 17. Evidence for tankyrases as antineoplastic targets in lung cancer.
    Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ.
    BMC Cancer; 2013 Apr 28; 13():211. PubMed ID: 23621985
    [Abstract] [Full Text] [Related]

  • 18. β-Catenin signaling in hepatocellular carcinoma.
    Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X.
    J Clin Invest; 2022 Feb 15; 132(4):. PubMed ID: 35166233
    [Abstract] [Full Text] [Related]

  • 19. APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.
    Tanaka N, Mashima T, Mizutani A, Sato A, Aoyama A, Gong B, Yoshida H, Muramatsu Y, Nakata K, Matsuura M, Katayama R, Nagayama S, Fujita N, Sugimoto Y, Seimiya H.
    Mol Cancer Ther; 2017 Apr 15; 16(4):752-762. PubMed ID: 28179481
    [Abstract] [Full Text] [Related]

  • 20. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling.
    Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, Liu PS, Bheddah S, Tao J, Lill JR, Hongo JA, Davis D, Kirkpatrick DS, Polakis P, Costa M.
    PLoS One; 2011 Apr 15; 6(7):e22595. PubMed ID: 21799911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.